Global Bispecific Antibody Market

Bispecific Antibody Comprehensive Study by Application (Diagnosis of Bacterial Infections, Diagnosis of Viral Infections, BsMAb for Cancer Diagnostic, BsAbs Blocking Signaling Pathways, BsAbs Targeting Tumor Angiogenesis), Design (Bispecific Diabodies, Bispecific T-Cell Engager Antibodies (BiTEs)), Mechanism of Action (Trifunctional Antibody (Catumaxomab), Blinatumomab) Players and Region - Global Market Outlook to 2027

Bispecific Antibody Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Bispecific Antibodies combine two or more antigen-recognizing elements into a single construct, able to bind to two or more targets. This accounts for the fact that more than one pathway is often at the root of the disease. Bispecific antibodies are capable of binding into two or more targets at a time. Moreover, these antibodies might channel two targets together and are able to present high probabilities of gaining therapeutic effects.This growth is primarily driven by Increasing Applications of Bispecific Antibodies for Cancer Systems.

AttributesDetails
Study Period2017-2027
Base Year2021
Forecast Period2022-2027
Historical Period2017-2021
UnitValue (USD Million)
Key Companies in StudyAblynx (Belgium), Adimab (United States), Affimed Therapeutics (Germany), Amgen (United States), AstraZeneca (MedImmune) (United States), Chugai Pharmaceutical (Japan), Eli Lilly (United States), EMD Serono (United States), Neovii Biotech (Germany), NovImmune SA (Switzerland), Roche (Switzerland) and Sanofi (France)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Globally, a noticeable market trend is evident Rising Acceptance of Clinicians and Patients Due To Their Targeted Effect. Major Players, such as Ablynx (Belgium), Adimab (United States), Affimed Therapeutics (Germany), Amgen (United States), AstraZeneca (MedImmune) (United States), Chugai Pharmaceutical (Japan), Eli Lilly (United States), EMD Serono (United States), Neovii Biotech (Germany), NovImmune SA (Switzerland), Roche (Switzerland) and Sanofi (France) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In January 2021, Loxo Oncology, Eli Lilly, and Merus NV, a clinical-stage oncology company announced a collaboration to discover Novel T-Cell Re-Directing Bispecific Antibodies. Collaboration with Loxo Oncology and Eli Lilly will open exciting possibilities for Merus' Biclonics platform. However, Merus is also looking to work together with Loxo Oncology in order to develop a next-generation of medicine that is used to treat cancer.
In July 2021, Amgen announced the acquisition of Teneobio to develop a new class of biologics called Human Heavy-Chain Antibodies. The acquisition of Teneobio includes a portfolio of early-stage oncology assets including a Phase 1 bispecific antibody for patients With advanced prostate cancer. The acquisition will strengthen Amgen's ability in the development of innovative medicines to treat patients with serious illnesses and bring best-in-class products to the market.

Market Drivers
  • Increasing Applications of Bispecific Antibodies for Cancer Systems

Market Trend
  • Rising Acceptance of Clinicians and Patients Due To Their Targeted Effect

Restraints
  • Complex Purification Process
  • Technical Complexity Associated With the Treatment Procedure of Bispecific Antibodies

Opportunities
Increasing Number of Big and Small Pharmaceutical Companies
Challenges
Monetary Restrictions for Manufacturers As Well As the Consumers and High Cost related to Bispecific Antibodies

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Bispecific Antibody Study Sheds Light on
— The Bispecific Antibody Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Bispecific Antibody industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Bispecific Antibody industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Application
  • Diagnosis of Bacterial Infections
  • Diagnosis of Viral Infections
  • BsMAb for Cancer Diagnostic
  • BsAbs Blocking Signaling Pathways
  • BsAbs Targeting Tumor Angiogenesis
By Design
  • Bispecific Diabodies
  • Bispecific T-Cell Engager Antibodies (BiTEs)

By Mechanism of Action
  • Trifunctional Antibody (Catumaxomab)
  • Blinatumomab

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Applications of Bispecific Antibodies for Cancer Systems
    • 3.3. Market Challenges
      • 3.3.1. Monetary Restrictions for Manufacturers As Well As the Consumers
      • 3.3.2. High Cost related to Bispecific Antibodies
    • 3.4. Market Trends
      • 3.4.1. Rising Acceptance of Clinicians and Patients Due To Their Targeted Effect
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Bispecific Antibody, by Application, Design, Mechanism of Action and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Bispecific Antibody (Value)
      • 5.2.1. Global Bispecific Antibody by: Application (Value)
        • 5.2.1.1. Diagnosis of Bacterial Infections
        • 5.2.1.2. Diagnosis of Viral Infections
        • 5.2.1.3. BsMAb for Cancer Diagnostic
        • 5.2.1.4. BsAbs Blocking Signaling Pathways
        • 5.2.1.5. BsAbs Targeting Tumor Angiogenesis
      • 5.2.2. Global Bispecific Antibody by: Design (Value)
        • 5.2.2.1. Bispecific Diabodies
        • 5.2.2.2. Bispecific T-Cell Engager Antibodies (BiTEs)
      • 5.2.3. Global Bispecific Antibody by: Mechanism of Action (Value)
        • 5.2.3.1. Trifunctional Antibody (Catumaxomab)
        • 5.2.3.2. Blinatumomab
      • 5.2.4. Global Bispecific Antibody Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Bispecific Antibody (Price)
  • 6. Bispecific Antibody: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Ablynx (Belgium)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Adimab (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Affimed Therapeutics (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Amgen (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AstraZeneca (MedImmune) (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Chugai Pharmaceutical (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Eli Lilly (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. EMD Serono (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Neovii Biotech (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. NovImmune SA (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Roche (Switzerland)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Sanofi (France)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Bispecific Antibody Sale, by Application, Design, Mechanism of Action and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Bispecific Antibody (Value)
      • 7.2.1. Global Bispecific Antibody by: Application (Value)
        • 7.2.1.1. Diagnosis of Bacterial Infections
        • 7.2.1.2. Diagnosis of Viral Infections
        • 7.2.1.3. BsMAb for Cancer Diagnostic
        • 7.2.1.4. BsAbs Blocking Signaling Pathways
        • 7.2.1.5. BsAbs Targeting Tumor Angiogenesis
      • 7.2.2. Global Bispecific Antibody by: Design (Value)
        • 7.2.2.1. Bispecific Diabodies
        • 7.2.2.2. Bispecific T-Cell Engager Antibodies (BiTEs)
      • 7.2.3. Global Bispecific Antibody by: Mechanism of Action (Value)
        • 7.2.3.1. Trifunctional Antibody (Catumaxomab)
        • 7.2.3.2. Blinatumomab
      • 7.2.4. Global Bispecific Antibody Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Bispecific Antibody (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Bispecific Antibody: by Application(USD Million)
  • Table 2. Bispecific Antibody Diagnosis of Bacterial Infections , by Region USD Million (2016-2021)
  • Table 3. Bispecific Antibody Diagnosis of Viral Infections , by Region USD Million (2016-2021)
  • Table 4. Bispecific Antibody BsMAb for Cancer Diagnostic , by Region USD Million (2016-2021)
  • Table 5. Bispecific Antibody BsAbs Blocking Signaling Pathways , by Region USD Million (2016-2021)
  • Table 6. Bispecific Antibody BsAbs Targeting Tumor Angiogenesis , by Region USD Million (2016-2021)
  • Table 7. Bispecific Antibody: by Design(USD Million)
  • Table 8. Bispecific Antibody Bispecific Diabodies , by Region USD Million (2016-2021)
  • Table 9. Bispecific Antibody Bispecific T-Cell Engager Antibodies (BiTEs) , by Region USD Million (2016-2021)
  • Table 10. Bispecific Antibody: by Mechanism of Action(USD Million)
  • Table 11. Bispecific Antibody Trifunctional Antibody (Catumaxomab) , by Region USD Million (2016-2021)
  • Table 12. Bispecific Antibody Blinatumomab , by Region USD Million (2016-2021)
  • Table 13. South America Bispecific Antibody, by Country USD Million (2016-2021)
  • Table 14. South America Bispecific Antibody, by Application USD Million (2016-2021)
  • Table 15. South America Bispecific Antibody, by Design USD Million (2016-2021)
  • Table 16. South America Bispecific Antibody, by Mechanism of Action USD Million (2016-2021)
  • Table 17. Brazil Bispecific Antibody, by Application USD Million (2016-2021)
  • Table 18. Brazil Bispecific Antibody, by Design USD Million (2016-2021)
  • Table 19. Brazil Bispecific Antibody, by Mechanism of Action USD Million (2016-2021)
  • Table 20. Argentina Bispecific Antibody, by Application USD Million (2016-2021)
  • Table 21. Argentina Bispecific Antibody, by Design USD Million (2016-2021)
  • Table 22. Argentina Bispecific Antibody, by Mechanism of Action USD Million (2016-2021)
  • Table 23. Rest of South America Bispecific Antibody, by Application USD Million (2016-2021)
  • Table 24. Rest of South America Bispecific Antibody, by Design USD Million (2016-2021)
  • Table 25. Rest of South America Bispecific Antibody, by Mechanism of Action USD Million (2016-2021)
  • Table 26. Asia Pacific Bispecific Antibody, by Country USD Million (2016-2021)
  • Table 27. Asia Pacific Bispecific Antibody, by Application USD Million (2016-2021)
  • Table 28. Asia Pacific Bispecific Antibody, by Design USD Million (2016-2021)
  • Table 29. Asia Pacific Bispecific Antibody, by Mechanism of Action USD Million (2016-2021)
  • Table 30. China Bispecific Antibody, by Application USD Million (2016-2021)
  • Table 31. China Bispecific Antibody, by Design USD Million (2016-2021)
  • Table 32. China Bispecific Antibody, by Mechanism of Action USD Million (2016-2021)
  • Table 33. Japan Bispecific Antibody, by Application USD Million (2016-2021)
  • Table 34. Japan Bispecific Antibody, by Design USD Million (2016-2021)
  • Table 35. Japan Bispecific Antibody, by Mechanism of Action USD Million (2016-2021)
  • Table 36. India Bispecific Antibody, by Application USD Million (2016-2021)
  • Table 37. India Bispecific Antibody, by Design USD Million (2016-2021)
  • Table 38. India Bispecific Antibody, by Mechanism of Action USD Million (2016-2021)
  • Table 39. South Korea Bispecific Antibody, by Application USD Million (2016-2021)
  • Table 40. South Korea Bispecific Antibody, by Design USD Million (2016-2021)
  • Table 41. South Korea Bispecific Antibody, by Mechanism of Action USD Million (2016-2021)
  • Table 42. Taiwan Bispecific Antibody, by Application USD Million (2016-2021)
  • Table 43. Taiwan Bispecific Antibody, by Design USD Million (2016-2021)
  • Table 44. Taiwan Bispecific Antibody, by Mechanism of Action USD Million (2016-2021)
  • Table 45. Australia Bispecific Antibody, by Application USD Million (2016-2021)
  • Table 46. Australia Bispecific Antibody, by Design USD Million (2016-2021)
  • Table 47. Australia Bispecific Antibody, by Mechanism of Action USD Million (2016-2021)
  • Table 48. Rest of Asia-Pacific Bispecific Antibody, by Application USD Million (2016-2021)
  • Table 49. Rest of Asia-Pacific Bispecific Antibody, by Design USD Million (2016-2021)
  • Table 50. Rest of Asia-Pacific Bispecific Antibody, by Mechanism of Action USD Million (2016-2021)
  • Table 51. Europe Bispecific Antibody, by Country USD Million (2016-2021)
  • Table 52. Europe Bispecific Antibody, by Application USD Million (2016-2021)
  • Table 53. Europe Bispecific Antibody, by Design USD Million (2016-2021)
  • Table 54. Europe Bispecific Antibody, by Mechanism of Action USD Million (2016-2021)
  • Table 55. Germany Bispecific Antibody, by Application USD Million (2016-2021)
  • Table 56. Germany Bispecific Antibody, by Design USD Million (2016-2021)
  • Table 57. Germany Bispecific Antibody, by Mechanism of Action USD Million (2016-2021)
  • Table 58. France Bispecific Antibody, by Application USD Million (2016-2021)
  • Table 59. France Bispecific Antibody, by Design USD Million (2016-2021)
  • Table 60. France Bispecific Antibody, by Mechanism of Action USD Million (2016-2021)
  • Table 61. Italy Bispecific Antibody, by Application USD Million (2016-2021)
  • Table 62. Italy Bispecific Antibody, by Design USD Million (2016-2021)
  • Table 63. Italy Bispecific Antibody, by Mechanism of Action USD Million (2016-2021)
  • Table 64. United Kingdom Bispecific Antibody, by Application USD Million (2016-2021)
  • Table 65. United Kingdom Bispecific Antibody, by Design USD Million (2016-2021)
  • Table 66. United Kingdom Bispecific Antibody, by Mechanism of Action USD Million (2016-2021)
  • Table 67. Netherlands Bispecific Antibody, by Application USD Million (2016-2021)
  • Table 68. Netherlands Bispecific Antibody, by Design USD Million (2016-2021)
  • Table 69. Netherlands Bispecific Antibody, by Mechanism of Action USD Million (2016-2021)
  • Table 70. Rest of Europe Bispecific Antibody, by Application USD Million (2016-2021)
  • Table 71. Rest of Europe Bispecific Antibody, by Design USD Million (2016-2021)
  • Table 72. Rest of Europe Bispecific Antibody, by Mechanism of Action USD Million (2016-2021)
  • Table 73. MEA Bispecific Antibody, by Country USD Million (2016-2021)
  • Table 74. MEA Bispecific Antibody, by Application USD Million (2016-2021)
  • Table 75. MEA Bispecific Antibody, by Design USD Million (2016-2021)
  • Table 76. MEA Bispecific Antibody, by Mechanism of Action USD Million (2016-2021)
  • Table 77. Middle East Bispecific Antibody, by Application USD Million (2016-2021)
  • Table 78. Middle East Bispecific Antibody, by Design USD Million (2016-2021)
  • Table 79. Middle East Bispecific Antibody, by Mechanism of Action USD Million (2016-2021)
  • Table 80. Africa Bispecific Antibody, by Application USD Million (2016-2021)
  • Table 81. Africa Bispecific Antibody, by Design USD Million (2016-2021)
  • Table 82. Africa Bispecific Antibody, by Mechanism of Action USD Million (2016-2021)
  • Table 83. North America Bispecific Antibody, by Country USD Million (2016-2021)
  • Table 84. North America Bispecific Antibody, by Application USD Million (2016-2021)
  • Table 85. North America Bispecific Antibody, by Design USD Million (2016-2021)
  • Table 86. North America Bispecific Antibody, by Mechanism of Action USD Million (2016-2021)
  • Table 87. United States Bispecific Antibody, by Application USD Million (2016-2021)
  • Table 88. United States Bispecific Antibody, by Design USD Million (2016-2021)
  • Table 89. United States Bispecific Antibody, by Mechanism of Action USD Million (2016-2021)
  • Table 90. Canada Bispecific Antibody, by Application USD Million (2016-2021)
  • Table 91. Canada Bispecific Antibody, by Design USD Million (2016-2021)
  • Table 92. Canada Bispecific Antibody, by Mechanism of Action USD Million (2016-2021)
  • Table 93. Mexico Bispecific Antibody, by Application USD Million (2016-2021)
  • Table 94. Mexico Bispecific Antibody, by Design USD Million (2016-2021)
  • Table 95. Mexico Bispecific Antibody, by Mechanism of Action USD Million (2016-2021)
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Bispecific Antibody: by Application(USD Million)
  • Table 109. Bispecific Antibody Diagnosis of Bacterial Infections , by Region USD Million (2022-2027)
  • Table 110. Bispecific Antibody Diagnosis of Viral Infections , by Region USD Million (2022-2027)
  • Table 111. Bispecific Antibody BsMAb for Cancer Diagnostic , by Region USD Million (2022-2027)
  • Table 112. Bispecific Antibody BsAbs Blocking Signaling Pathways , by Region USD Million (2022-2027)
  • Table 113. Bispecific Antibody BsAbs Targeting Tumor Angiogenesis , by Region USD Million (2022-2027)
  • Table 114. Bispecific Antibody: by Design(USD Million)
  • Table 115. Bispecific Antibody Bispecific Diabodies , by Region USD Million (2022-2027)
  • Table 116. Bispecific Antibody Bispecific T-Cell Engager Antibodies (BiTEs) , by Region USD Million (2022-2027)
  • Table 117. Bispecific Antibody: by Mechanism of Action(USD Million)
  • Table 118. Bispecific Antibody Trifunctional Antibody (Catumaxomab) , by Region USD Million (2022-2027)
  • Table 119. Bispecific Antibody Blinatumomab , by Region USD Million (2022-2027)
  • Table 120. South America Bispecific Antibody, by Country USD Million (2022-2027)
  • Table 121. South America Bispecific Antibody, by Application USD Million (2022-2027)
  • Table 122. South America Bispecific Antibody, by Design USD Million (2022-2027)
  • Table 123. South America Bispecific Antibody, by Mechanism of Action USD Million (2022-2027)
  • Table 124. Brazil Bispecific Antibody, by Application USD Million (2022-2027)
  • Table 125. Brazil Bispecific Antibody, by Design USD Million (2022-2027)
  • Table 126. Brazil Bispecific Antibody, by Mechanism of Action USD Million (2022-2027)
  • Table 127. Argentina Bispecific Antibody, by Application USD Million (2022-2027)
  • Table 128. Argentina Bispecific Antibody, by Design USD Million (2022-2027)
  • Table 129. Argentina Bispecific Antibody, by Mechanism of Action USD Million (2022-2027)
  • Table 130. Rest of South America Bispecific Antibody, by Application USD Million (2022-2027)
  • Table 131. Rest of South America Bispecific Antibody, by Design USD Million (2022-2027)
  • Table 132. Rest of South America Bispecific Antibody, by Mechanism of Action USD Million (2022-2027)
  • Table 133. Asia Pacific Bispecific Antibody, by Country USD Million (2022-2027)
  • Table 134. Asia Pacific Bispecific Antibody, by Application USD Million (2022-2027)
  • Table 135. Asia Pacific Bispecific Antibody, by Design USD Million (2022-2027)
  • Table 136. Asia Pacific Bispecific Antibody, by Mechanism of Action USD Million (2022-2027)
  • Table 137. China Bispecific Antibody, by Application USD Million (2022-2027)
  • Table 138. China Bispecific Antibody, by Design USD Million (2022-2027)
  • Table 139. China Bispecific Antibody, by Mechanism of Action USD Million (2022-2027)
  • Table 140. Japan Bispecific Antibody, by Application USD Million (2022-2027)
  • Table 141. Japan Bispecific Antibody, by Design USD Million (2022-2027)
  • Table 142. Japan Bispecific Antibody, by Mechanism of Action USD Million (2022-2027)
  • Table 143. India Bispecific Antibody, by Application USD Million (2022-2027)
  • Table 144. India Bispecific Antibody, by Design USD Million (2022-2027)
  • Table 145. India Bispecific Antibody, by Mechanism of Action USD Million (2022-2027)
  • Table 146. South Korea Bispecific Antibody, by Application USD Million (2022-2027)
  • Table 147. South Korea Bispecific Antibody, by Design USD Million (2022-2027)
  • Table 148. South Korea Bispecific Antibody, by Mechanism of Action USD Million (2022-2027)
  • Table 149. Taiwan Bispecific Antibody, by Application USD Million (2022-2027)
  • Table 150. Taiwan Bispecific Antibody, by Design USD Million (2022-2027)
  • Table 151. Taiwan Bispecific Antibody, by Mechanism of Action USD Million (2022-2027)
  • Table 152. Australia Bispecific Antibody, by Application USD Million (2022-2027)
  • Table 153. Australia Bispecific Antibody, by Design USD Million (2022-2027)
  • Table 154. Australia Bispecific Antibody, by Mechanism of Action USD Million (2022-2027)
  • Table 155. Rest of Asia-Pacific Bispecific Antibody, by Application USD Million (2022-2027)
  • Table 156. Rest of Asia-Pacific Bispecific Antibody, by Design USD Million (2022-2027)
  • Table 157. Rest of Asia-Pacific Bispecific Antibody, by Mechanism of Action USD Million (2022-2027)
  • Table 158. Europe Bispecific Antibody, by Country USD Million (2022-2027)
  • Table 159. Europe Bispecific Antibody, by Application USD Million (2022-2027)
  • Table 160. Europe Bispecific Antibody, by Design USD Million (2022-2027)
  • Table 161. Europe Bispecific Antibody, by Mechanism of Action USD Million (2022-2027)
  • Table 162. Germany Bispecific Antibody, by Application USD Million (2022-2027)
  • Table 163. Germany Bispecific Antibody, by Design USD Million (2022-2027)
  • Table 164. Germany Bispecific Antibody, by Mechanism of Action USD Million (2022-2027)
  • Table 165. France Bispecific Antibody, by Application USD Million (2022-2027)
  • Table 166. France Bispecific Antibody, by Design USD Million (2022-2027)
  • Table 167. France Bispecific Antibody, by Mechanism of Action USD Million (2022-2027)
  • Table 168. Italy Bispecific Antibody, by Application USD Million (2022-2027)
  • Table 169. Italy Bispecific Antibody, by Design USD Million (2022-2027)
  • Table 170. Italy Bispecific Antibody, by Mechanism of Action USD Million (2022-2027)
  • Table 171. United Kingdom Bispecific Antibody, by Application USD Million (2022-2027)
  • Table 172. United Kingdom Bispecific Antibody, by Design USD Million (2022-2027)
  • Table 173. United Kingdom Bispecific Antibody, by Mechanism of Action USD Million (2022-2027)
  • Table 174. Netherlands Bispecific Antibody, by Application USD Million (2022-2027)
  • Table 175. Netherlands Bispecific Antibody, by Design USD Million (2022-2027)
  • Table 176. Netherlands Bispecific Antibody, by Mechanism of Action USD Million (2022-2027)
  • Table 177. Rest of Europe Bispecific Antibody, by Application USD Million (2022-2027)
  • Table 178. Rest of Europe Bispecific Antibody, by Design USD Million (2022-2027)
  • Table 179. Rest of Europe Bispecific Antibody, by Mechanism of Action USD Million (2022-2027)
  • Table 180. MEA Bispecific Antibody, by Country USD Million (2022-2027)
  • Table 181. MEA Bispecific Antibody, by Application USD Million (2022-2027)
  • Table 182. MEA Bispecific Antibody, by Design USD Million (2022-2027)
  • Table 183. MEA Bispecific Antibody, by Mechanism of Action USD Million (2022-2027)
  • Table 184. Middle East Bispecific Antibody, by Application USD Million (2022-2027)
  • Table 185. Middle East Bispecific Antibody, by Design USD Million (2022-2027)
  • Table 186. Middle East Bispecific Antibody, by Mechanism of Action USD Million (2022-2027)
  • Table 187. Africa Bispecific Antibody, by Application USD Million (2022-2027)
  • Table 188. Africa Bispecific Antibody, by Design USD Million (2022-2027)
  • Table 189. Africa Bispecific Antibody, by Mechanism of Action USD Million (2022-2027)
  • Table 190. North America Bispecific Antibody, by Country USD Million (2022-2027)
  • Table 191. North America Bispecific Antibody, by Application USD Million (2022-2027)
  • Table 192. North America Bispecific Antibody, by Design USD Million (2022-2027)
  • Table 193. North America Bispecific Antibody, by Mechanism of Action USD Million (2022-2027)
  • Table 194. United States Bispecific Antibody, by Application USD Million (2022-2027)
  • Table 195. United States Bispecific Antibody, by Design USD Million (2022-2027)
  • Table 196. United States Bispecific Antibody, by Mechanism of Action USD Million (2022-2027)
  • Table 197. Canada Bispecific Antibody, by Application USD Million (2022-2027)
  • Table 198. Canada Bispecific Antibody, by Design USD Million (2022-2027)
  • Table 199. Canada Bispecific Antibody, by Mechanism of Action USD Million (2022-2027)
  • Table 200. Mexico Bispecific Antibody, by Application USD Million (2022-2027)
  • Table 201. Mexico Bispecific Antibody, by Design USD Million (2022-2027)
  • Table 202. Mexico Bispecific Antibody, by Mechanism of Action USD Million (2022-2027)
  • Table 203. Research Programs/Design for This Report
  • Table 204. Key Data Information from Secondary Sources
  • Table 205. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Bispecific Antibody: by Application USD Million (2016-2021)
  • Figure 5. Global Bispecific Antibody: by Design USD Million (2016-2021)
  • Figure 6. Global Bispecific Antibody: by Mechanism of Action USD Million (2016-2021)
  • Figure 7. South America Bispecific Antibody Share (%), by Country
  • Figure 8. Asia Pacific Bispecific Antibody Share (%), by Country
  • Figure 9. Europe Bispecific Antibody Share (%), by Country
  • Figure 10. MEA Bispecific Antibody Share (%), by Country
  • Figure 11. North America Bispecific Antibody Share (%), by Country
  • Figure 12. Global Bispecific Antibody share by Players 2021 (%)
  • Figure 13. Global Bispecific Antibody share by Players (Top 3) 2021(%)
  • Figure 14. Global Bispecific Antibody share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Ablynx (Belgium) Revenue, Net Income and Gross profit
  • Figure 17. Ablynx (Belgium) Revenue: by Geography 2021
  • Figure 18. Adimab (United States) Revenue, Net Income and Gross profit
  • Figure 19. Adimab (United States) Revenue: by Geography 2021
  • Figure 20. Affimed Therapeutics (Germany) Revenue, Net Income and Gross profit
  • Figure 21. Affimed Therapeutics (Germany) Revenue: by Geography 2021
  • Figure 22. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 23. Amgen (United States) Revenue: by Geography 2021
  • Figure 24. AstraZeneca (MedImmune) (United States) Revenue, Net Income and Gross profit
  • Figure 25. AstraZeneca (MedImmune) (United States) Revenue: by Geography 2021
  • Figure 26. Chugai Pharmaceutical (Japan) Revenue, Net Income and Gross profit
  • Figure 27. Chugai Pharmaceutical (Japan) Revenue: by Geography 2021
  • Figure 28. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 29. Eli Lilly (United States) Revenue: by Geography 2021
  • Figure 30. EMD Serono (United States) Revenue, Net Income and Gross profit
  • Figure 31. EMD Serono (United States) Revenue: by Geography 2021
  • Figure 32. Neovii Biotech (Germany) Revenue, Net Income and Gross profit
  • Figure 33. Neovii Biotech (Germany) Revenue: by Geography 2021
  • Figure 34. NovImmune SA (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. NovImmune SA (Switzerland) Revenue: by Geography 2021
  • Figure 36. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 37. Roche (Switzerland) Revenue: by Geography 2021
  • Figure 38. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 39. Sanofi (France) Revenue: by Geography 2021
  • Figure 40. Global Bispecific Antibody: by Application USD Million (2022-2027)
  • Figure 41. Global Bispecific Antibody: by Design USD Million (2022-2027)
  • Figure 42. Global Bispecific Antibody: by Mechanism of Action USD Million (2022-2027)
  • Figure 43. South America Bispecific Antibody Share (%), by Country
  • Figure 44. Asia Pacific Bispecific Antibody Share (%), by Country
  • Figure 45. Europe Bispecific Antibody Share (%), by Country
  • Figure 46. MEA Bispecific Antibody Share (%), by Country
  • Figure 47. North America Bispecific Antibody Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Ablynx (Belgium)
  • Adimab (United States)
  • Affimed Therapeutics (Germany)
  • Amgen (United States)
  • AstraZeneca (MedImmune) (United States)
  • Chugai Pharmaceutical (Japan)
  • Eli Lilly (United States)
  • EMD Serono (United States)
  • Neovii Biotech (Germany)
  • NovImmune SA (Switzerland)
  • Roche (Switzerland)
  • Sanofi (France)
Additional players considered in the study are as follows:
Emergent BioSolutions (United States) , Genentech (United States) , MacroGenics (United States) , Merus (Netherlands)
Select User Access Type

Key Highlights of Report


May 2022 148 Pages 80 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Bispecific Antibody Market Quantitative research analysis
Global Bispecific Antibody Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2017-2021; Base year: 2021; Forecast period: 2022 to 2027
Companies that are profiled in Global Bispecific Antibody Market are Ablynx (Belgium), Adimab (United States), Affimed Therapeutics (Germany), Amgen (United States), AstraZeneca (MedImmune) (United States), Chugai Pharmaceutical (Japan), Eli Lilly (United States), EMD Serono (United States), Neovii Biotech (Germany), NovImmune SA (Switzerland), Roche (Switzerland) and Sanofi (France) etc.
Diagnosis of Bacterial Infections segment in Global market to hold robust market share owing to "Increasing Applications of Bispecific Antibodies for Cancer Systems".
AMA Research predicts that United States Players will contribute to the maximum growth of Global Bispecific Antibody market throughout the forecasted period.

Know More About Global Bispecific Antibody Market Report?

Have a Query? Click Here

Other Related Reports

Soybean Trypsin Inhibitor Comprehensive Study by Type (Purity >90%, Purity >95%, Other), Application (Scientific Research, Industrial Production), Form (Powder, Liquid), End User (Pharmaceutical Comp...
$ 3350
Bioprocess Technology Comprehensive Study by Type (Cell Expansion, Cell Culture, Cell Line Development, Flow Cytometry, Virus Infiltration), Application (Specialty Products, Biopharmaceuticals, Envir...
$ 3650
Waste-to-Energy Technologies Comprehensive Study by Type (Thermal, Thermo-Chemical, Mechanical-Thermal, Biochemical), Application (Heat, Fuels, Electricity), Waste Type (Municipal Solid Waste (MSW), ...
$ 3800
Antibiotic Residue Test Kits Comprehensive Study by Sales Channel (Online, Offline), End-Use (Food and Beverage Industry, Veterinary, Independent Laboratory, Others), Test Type (Beta-lactams, Macroli...
$ 3450
Branched Chain Amino Acids Comprehensive Study by Type (Proteinogenic {Leucine, Isoleucine and Valine}, Non-Proteinogenic {2-Aminoisobutyric Acid}), Application (Food & Beverages, Animal Feed, Pharma...
$ 3650
Anaerobic Incubators Comprehensive Study by Type (Workstation, Glove Box), Application (Environment Industry, Microbial Engineering, Other), Components (LED Screen Display, Temperature-Control, UV La...
$ 3650